Portmanteau inhibitor explained

A portmanteau inhibitor is a drug that is a combination of two drug molecules, each of which is itself a type of inhibitor. The term was coined in 2007 by University of Minnesota researchers who designed and synthesized a combination HIV reverse transcriptase inhibitor and an integrase inhibitor,[1] [2] [3] and was further used in 2011 by a team of researchers combining an integrase inhibitor with a CCR5 entry inhibitor.[4]

Footnotes

  1. Web site: U of M researchers announce advance in treatment of HIV. 25 July 2007. 25 July 2007.
  2. Web site: Researchers Discover New Method To Combat HIV. 25 July 2007. 25 July 2007.
  3. 17608468. Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase. Zhengqiang Wang. Eric M. Bennett. Daniel J. Wilson. Christine Salomon. Robert Vince . Robert Vince (scientist) . Journal of Medicinal Chemistry. 2007. 50. 15. 3416–3419. 10.1021/jm070512p. 10.1.1.535.8472.
  4. Bodiwala . H. S. . Sabde . S. . Gupta . P. . Mukherjee . R. . Kumar . R. . Garg . P. . Bhutani . K. K. . Mitra . D. . Singh . I. P. . 10.1016/j.bmc.2010.12.031 . Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5 . Bioorganic & Medicinal Chemistry . 19 . 3 . 1256–63 . 2011 . 21227704.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Portmanteau inhibitor".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.